Ueno H, Takata M, Oh-hashi S, Tomoda F, Yasumoto K, Inoue H
Second Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Japan.
J Hum Hypertens. 1995 Sep;9(9):735-9.
The objective of this study was to assess the regression of vascular structural changes seen in essential hypertension after long-term monotherapy with a calcium antagonist and to clarify the relations to cytosolic free calcium and neurohumoral factors. Blood pressure, minimal vascular resistance (MVR) by strain-gauge plethysmography, cytosolic free calcium in platelets ([Ca2+]i) by Quin 2 method, plasma renin activity (PRA) and plasma aldosterone concentration (PAC), plasma noradrenaline (PNA) and parathyroid hormone (PTH) were measured in 14 essential hypertensives during a placebo period and 2 and 6 months after anti-hypertensive treatment with nilvadipine. Blood pressure decreased from 174 +/- 10/104 +/- 8 mm Hg during the placebo period to 154 +/- 13/93 +/- 14 mm Hg 2 weeks after nilvadipine, and the hypotensive effects were found throughout the 6-month period. Although increased MVR seen in hypertensives did not change after 2 months (from 2.1 +/- 0.7 to 1.9 +/- 0.6 mm Hg/ml/min per 100 ml tissue (PRU), NS), MVR decreased significantly at 6 months (1.6 +/- 0.4, PRU, P < 0.05). Elevated [Ca2+]i seen in hypertensives during the placebo period decreased significantly 2 months after nilvadipine treatment (156 +/- 26 and 140 +/- 27 nM, P < 0.01). The changes in MVR were associated with those in [Ca2+]i 6 months after nilvadipine (r = 0.56, P < 0.05). However, the changes in MVR did not correlate with those in PRA, PAC, PNA or PTH.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究的目的是评估长期使用钙拮抗剂单一疗法后原发性高血压患者血管结构变化的消退情况,并阐明其与细胞内游离钙及神经体液因子的关系。对14例原发性高血压患者在安慰剂期以及使用尼伐地平进行抗高血压治疗2个月和6个月后,测量其血压、通过应变片体积描记法测得的最小血管阻力(MVR)、用喹啉2法测得的血小板细胞内游离钙([Ca2+]i)、血浆肾素活性(PRA)、血浆醛固酮浓度(PAC)、血浆去甲肾上腺素(PNA)和甲状旁腺激素(PTH)。血压在安慰剂期为174±10/104±8 mmHg,在尼伐地平治疗2周后降至154±13/93±14 mmHg,且在整个6个月期间均有降压作用。高血压患者中升高的MVR在2个月后未改变(从2.1±0.7至1.9±0.6 mmHg/ml/min per 100 ml组织(PRU),无显著性差异),但在6个月时MVR显著降低(1.6±0.4,PRU,P<0.05)。安慰剂期高血压患者中升高的[Ca2+]i在尼伐地平治疗2个月后显著降低(156±26和140±27 nM,P<0.01)。尼伐地平治疗6个月后MVR的变化与[Ca2+]i的变化相关(r = 0.56,P<0.05)。然而,MVR的变化与PRA、PAC、PNA或PTH的变化无关。(摘要截短至250字)